To test our hypothesis that SEMA7A plays a role in progression of DCIS in patients, we examined SEMA7A expression in Early Stage Breast Tumors (SCAN-B) for breast cancers by biopsy type and found that SEMA7A mRNA is upregulated in invasive carcinomas compared to in situ carcinomas (Supp Fig. 1A). This evidence concerns the gene SEMA7A and in situ carcinoma.